LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia
29. April 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide™ Platform Development and Advancement of Lead Program into Clinic
22. April 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
01. April 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
LogicBio Therapeutics to Present at Upcoming March Conferences
25. Februar 2019 07:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development
22. Februar 2019 07:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors
06. Dezember 2018 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio Reports Third Quarter 2018 Financial Results
03. Dezember 2018 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
LogicBio Announces Partnership with Children’s Medical Research Institute to Develop Next Generation Viral Vectors
15. November 2018 06:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ: LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
LogicBio to Present at the Jefferies 2018 London Healthcare Conference
13. November 2018 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients...
LogicBio Therapeutics Announces Closing of Initial Public Offering
23. Oktober 2018 16:05 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients...